Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

Rhea-AI Summary

Esperion (NASDAQ: ESPR) to report Q4 and full year 2023 financial results on February 27, 2024. Webcast to discuss financial results and business updates. Esperion focuses on innovative medicines for cardiovascular and cardiometabolic diseases.

ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.

Already registered? Access with your PIN here. 

A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Esperion Contact Information:
Investors:
Alexis Callahan
investorrelations@esperion.com
(406) 539-1762
  
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion report its Q4 and full year 2023 financial results?

Esperion will report its fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024.

What time will the webcast to discuss financial results and business updates be held?

The webcast to discuss financial results and provide business updates will be held at 8:00 a.m. ET.

Where can investors access the live audio webcast?

Investors can access the live audio webcast on the investor and media section of the Esperion website.

How long will the webcast replay be available?

The webcast replay will be available approximately two hours after the call and will be archived on the Company's website for around 90 days.

What is Esperion's focus in terms of medicines?

Esperion focuses on discovering, developing, and commercializing innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.